InventisBio (SH:688382) Xin Lang Cai Jing·2026-02-26 10:25Core Viewpoint - The company, Yifang Biotechnology (688382.SH), is expected to experience a decline in revenue and an increase in net losses for the fiscal year 2025 compared to the previous year [1] Group 1: Revenue Expectations - For the fiscal year 2025, the company anticipates achieving a revenue of 37.3253 million yuan, which represents a decrease compared to the same period last year [1] - The primary source of the company's revenue currently comes from licensing and collaboration agreements, with variations in income from these sources across different years [1] Group 2: Profitability Outlook - The company projects a net loss attributable to shareholders of 317 million yuan for 2025, indicating a worsening loss situation compared to the previous year [1] - The expected net loss attributable to shareholders after excluding non-recurring gains and losses is projected to be 329 million yuan, also reflecting an increase in losses year-over-year [1] Group 3: Research and Development Investment - The company maintains a high level of research and development investment, which is not currently covered by the income from technology licensing and collaboration, leading to anticipated losses in 2025 [1]